Blogs & Insights
Explore the latest in biotech and research, crafted to inspire your next breakthrough.
New Updates
Dual-Target siRNA: the Future of RNAi Therapeutics
View Details
How to Choose the Right Alzheimer's Disease Research Model
View Details
Three Novartis Clinical Setbacks in Eight Days: What CAR-T, Pelacarsen, and Del-Desiran Reveal About Translational Risk
View Details
Beyond Topo I: Why Genentech’s $1B Deal with DualityBio Signals the Next Phase of ADC Development
View Details
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Filter By
All Topics
Animal Science and Quality
Autoimmunity & Inflammation
Cardiovascular Research
Cell & Gene Therapy
Genetic Disorders and Genomics
HUGO-Ab
Immunology
Infectious Diseases & Vaccines
Metabolism & Obesity
Neuroscience
Oncology
Ophthalmology
Precision Medicine & Biomarkers
Rare Diseases
Regenerative Biology
Milestones & Highlights
Filter By
Metabolism & Obesity
Dual-Target siRNA: the Future of RNAi Therapeutics
View Details
Neuroscience
How to Choose the Right Alzheimer's Disease Research Model
View Details
Animal Science and Quality
Three Novartis Clinical Setbacks in Eight Days: What CAR-T, Pelacarsen, and Del-Desiran Reveal About Translational Risk
View Details
HUGO-Ab
Beyond Topo I: Why Genentech’s $1B Deal with DualityBio Signals the Next Phase of ADC Development
View Details
Metabolism & Obesity
Is INHBE Only Half of the Activin Story?
View Details
Oncology
Enhertu’s First-Line Phase III Win in HER2-Mutant NSCLC: Are ADCs Moving into Precision Frontline Therapy?
View Details
HUGO-Ab
Breaking Immune Tolerance to ACVR2A: A Fully Human Antibody Strategy for Muscle and Metabolic Disease
View Details
Autoimmunity & Inflammation
Sonelokimab Phase III Win Puts the IL-17A/F Nanobody Strategy in Focus
View Details
Autoimmunity & Inflammation
Beyond Type 2 Inflammation: The Next Decade of IL-4Rα Therapeutics and the Humanized Mouse Model Breakthrough
View Details
1
2
3
4
5
6
...
21
22
More